In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor
patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of …

EGF receptor (EGFR)–mutant lung cancers eventually become resistant to treatment with
EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR …

The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many
types of solid tumour. Various therapeutics targeting these receptors have been approved …

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …

EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib)
develop acquired resistance, mediated by second-site EGFR T790M mutation in> 50% of …

Background: The epidermal growth factor receptor (EGFR) mutation T790M is reported in
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …

In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into
subtypes based on genotype and histology has resulted in dramatic improvements in …

Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …